Imaging and treatment of pathophysiologic conditions by Cerenkov radiation
The present disclosure discloses methods and compositions for administering Cerenkov radiation-induced therapy (CRIT). In an aspect, the invention encompasses a composition comprising at least two radiation-sensitive molecules. In another aspect, the invention encompasses a composition comprising a radiation-sensitive molecule and a targeting agent. In still another aspect, the invention encompasses a method for administering Cerenkov radiation-induced therapy (CRIT) to a target tissue in a subject. The method comprises administering to the subject an effective amount of a composition B comprising at least one radiation-sensitive molecule and administering to the subject an amount of a Cerenkov radiation (CR)-emitting radionuclide effective to activate the radiation-sensitive molecule, thereby administering CRIT to the target tissue in the subject.
1. A composition, the composition comprising a biocompatible inorganic nanoparticle comprised of at least one of ZnO, Si, TiO 2 , CdSe, CdS, InP, PbS, or PbSe, wherein the nanoparticle is coated with a target agent, wherein the target agent is further bound to a photoinitiator.
2. The composition of claim 1 , wherein the nanoparticle is further coated with polyethylene glycol (PEG), dextran, pullulan, glycolipid, hyaluronic acid, orosomucoid, heparin, chitosan, pectin, a polysaccharide, or a combination thereof.
3. The composition of claim 1 , where in the target agent is a polypeptide, an antigen, a nucleic acid, a polysaccharide, a sugar, a fatty acid, a steroid, a purine, a pyrimidine, a ligand, an aptamer, a small molecule, albumin, or combinations thereof.
4. The composition of claim 3 , where in the target agent is transferrin.
5. The composition of claim 1 , where the photoinitiator comprises acetophenone, benzyl and benzoin compounds, benzophenone, cationic photoinitiators, thioxanthones, or a combination thereof.
6. The composition of claim 5 , where the photoinitiator is a biocompatible photoinitiator comprised of at least one of titanocene, titanocene dichloride, 2 hydroxy-1-[4-(hydroxyethoxy)phenyl]-2-methyl-1-propanone, 2 hydroxy-1-[4-(hydroxyethoxy)phenyl]-1-propanone, 1 hydroxycyclohexane acetophenone, 2,2-dymethoxy-2-phenyl acetophenone, THX (thioxanthone), Eosin Y, camphorquinone, camphorquinone derivatives, BAPO (bisacylphosphine oxide bis(2,4,6-trimethylbenzoyl) phenylphosphineoxide), and HAP (hydroxyalkylphenone).
7. The composition of claim 6 , where the biocompatible photoinitiator is titanocene.
8. The composition of claim 1 , comprising a biocompatible inorganic TiO 2 nanoparticle coated with transferrin, wherein the transferrin is further bound to titanocene.
9. The composition of claim 8 , wherein the composition is capable of being activated by Cerenkov radiation (CR)-emitting radionuclides.
10. The composition of claim 9 , wherein the CR-emitting radionuclides are selected from the group consisting of 18 F, 18 F-FDG, 64 Cu, 90 Y, 124 I, and 89 Zr.
11. The composition of claim 1 , wherein the composition is capable of being activated by Cerenkov radiation (CR)-emitting radionuclides.
12. The composition of claim 11 , wherein the CR-emitting radionuclides are selected from the group consisting of 18 F, 18 F-FDG, 64 Cu, 90 Y, 124 I, and 89 Zr.
13. A method for administering Cerenkov radiation (CR)-induced therapy (CRIT) to a target tissue in a subject, the method comprising:
a. administering to the subject a composition of claim 1 and
b. administering to the subject an amount of a CR-emitting radionuclide effective to activate the composition of claim 1 , thereby administering CRIT to the target tissue in the subject.
14. The method of claim 13 , wherein administering CRIT to a target tissue is used to treat a disease associated with the target tissue.
15. A method for treating a tumor in a subject, the method comprising:
a. administering to the subject a composition of claim 1 ; and
b. administering to the subject an amount of a Cerenkov radiation (CR)-emitting radionuclide effective to activate the composition of claim 1 , thereby treating the tumor.